BMS Streamlining To Focus On Consumer Medicines, Nutritionals
This article was originally published in The Tan Sheet
Executive Summary
Bristol-Myers Squibb's decision to divest its Clairol cosmetics and Zimmer orthopedic implants businesses in the next 6 to 12 months is part of the company's strategy to focus its resources on its core medicines segments.
You may also be interested in...
Roche Vitamins Divestiture Will Not Occur Piecemeal, Chairman Says
Hoffman-La Roche's Vitamins & Fine Chemicals division could be sold to a raw material supplier without a substantial presence in vitamins or to a large food manufacturer
P&G Wins Clairol Bid Without Swapping OTCs
Procter & Gamble appears committed to strengthening its OTC drug portfolio in the wake of the firm's successful bid for the Clairol hair care business.
BMS Mead Johnson Impending Changes Continue Reorganization Efforts
An organizational shakeup at Mead Johnson is being executed by parent Bristol-Myers Squibb to help reverse disappointing results in recent quarters at the nutritionals division.